JANUMET Drug Patent Profile

Which patents cover Janumet, and when can generic versions of Janumet launch?

Janumet is a drug marketed by Msd Sub Merck and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in forty countries.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Janumet

Janumet was eligible for patent challenges on October 16, 2010.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry (peak sales were $2.6bn in 2020).

There have been forty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JANUMET

International Patents:	61
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	20
Drug Prices:	Drug price information for JANUMET
Drug Sales Revenues:	Drug sales revenues for JANUMET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUMET
What excipients (inactive ingredients) are in JANUMET?	JANUMET excipients list
DailyMed Link:	JANUMET at DailyMed

See drug prices for JANUMET

See drug sales revenues for JANUMET

Recent Clinical Trials for JANUMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Galenicum Health	Phase 1
Genuine Research Center, Egypt	Phase 1
Eva Pharma	Phase 1

See all JANUMET clinical trials

Pharmacology for JANUMET

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JANUMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET	Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	022044	5	2010-10-18

US Patents and Regulatory Information for JANUMET

JANUMET is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	AB	RX	Yes	No					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No					Y

Expired US Patents for JANUMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007

International Patents for JANUMET

See the table below for patents covering JANUMET around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	202705
Australia	3023397
Australia	721477

Supplementary Protection Certificates for JANUMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
1412357	PA2007006	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321
1412357	SPC/GB07/046	United Kingdom		PRODUCT NAME: SITAGLIPTIN PHOSPHATE MONOHYDRATE; REGISTERED: UK EU/1/07/383/001 20070323; UK EU/1/07/383/002 20070323; UK EU/1/07/383/003 20070323; UK EU/1/07/383/004 20070323; UK EU/1/07/383/005 20070323; UK EU/1/07/383/006 20070323; UK EU/1/07/383/007 20070323; UK EU/1/07/383/008 20070323; UK EU/1/07/383/009 20070323; UK EU/1/07/383/010 20070323; UK EU/1/07/383/011 20070323; UK EU/1/07/383/012 20070323; UK EU/1/07/383/013 20070323; UK EU/1/07/383/014 20070323; UK EU/1/07/383/015 20070323; UK EU/1/07/383/016 20070323; UK EU/1/07/383/017 20070323; UK EU/1/07/383/018 20070323

JANUMET (sitagliptin/metformin) market dynamics and financial trajectory: branded sales, competitor pressure, and exclusivity-driven risk

Last updated: July 23, 2026

JANUMET is a fixed-dose combination of sitagliptin and metformin that has faced sustained competitive pressure from lower-cost generic sitagliptin, metformin, and other branded DPP-4 inhibitors and incretin-based regimens. The commercial trajectory has increasingly shifted toward price erosion, payer consolidation, and formulary preference for generics and competing fixed-dose options, with gross-to-net compression tracking broader US and international diabetes pricing trends.

How did JANUMET sales evolve since launch, and what drives the financial trajectory now?

The financial trajectory of JANUMET is dominated by three forces: (1) ingredient-level generic substitution for sitagliptin and metformin, (2) incremental migration within diabetes formularies toward once-daily and/or single-tablet combination products, and (3) gross-to-net pressure from rebates, patient assistance, and contracting behavior as market share commoditized.

Core market dynamic. JANUMET competes in the broad type 2 diabetes oral therapy landscape where metformin remains the anchor, and sitagliptin competes in the DPP-4 class that has largely moved from branded differentiation to price-led competition. Once sitagliptin became broadly generic, fixed-dose branded combinations lost a meaningful cost advantage unless payers required adherence or reduced pill burden.

What typically sustains remaining branded share in DPP-4 combinations.

• Patient inertia and prescriber familiarity with fixed-dose regimens.
• Payer coverage decisions based on step edits, preferred product lists, or “brand-only” carveouts in narrow geographies.
• Co-pay assistance programs that reduce patient out-of-pocket cost for branded products when generics are not preferred tiered.

What patent and Orange Book status underpins JANUMET exclusivity, and when does it lose protection?

JANUMET’s exclusivity posture has historically been shaped by patent term and regulatory exclusivities around fixed-dose compositions, dosing regimens, and formulation/manufacturing improvements. As of current commercial reality, the branded product’s sales are primarily exposed to generic entry risks that occur when relevant Orange Book-listed patents expire or are overcome via Paragraph IV litigation or non-infringing carveouts.

Practical exclusivity timeline (commercial meaning).

• Once the relevant composition-of-matter and key formulation/manufacturing patents for sitagliptin/metformin fixed combinations were exhausted, generic fixed-dose competition or ingredient-level substitution materially accelerated price erosion.
• After key patent expirations, remaining branded demand generally tracks payer contracting cycles rather than legal exclusivity.

How to interpret today’s risk.

• If Orange Book listings are exhausted for JANUMET fixed-dose tablets in the key dose strengths, the main risk is not a single “cliff” but continued channel substitution over successive quarters.
• Any remaining method-of-use or formulation patents would affect specific generics only when their label/design design-arounds do not avoid the patented claims.

What generic entry risks exist for JANUMET tablets by strength and route?

JANUMET is marketed as oral tablets with multiple dose strengths (commonly including 50 mg sitagliptin combined with varying metformin strengths, and higher sitagliptin/metformin pairings). Generic entry risk is strongest when:

• A generic can match the same fixed-dose strengths and dosage form.
• The generic can secure FDA approval referencing the branded product labeling without triggering active, unexpired, non-design-around patent claims for that specific strength.

Typical market consequence of generic fixed-dose substitution.

• Gross-to-net rises for the brand as rebates and patient assistance increase to defend share.
• Net sales fall faster than unit volumes when payer systems shift to preferred generic fixed-dose alternatives.
• Remaining share concentrates among patients unable or unwilling to switch from JANUMET due to tolerability, pill burden preferences, or insurance barriers.

How do DPP-4 competitor dynamics affect JANUMET market share?

JANUMET’s competitive set includes other DPP-4 inhibitors and their fixed-dose combinations, plus broader class competitors (GLP-1 receptor agonists, SGLT2 inhibitors, and combinations). Even when the DPP-4 class remains in use, payer and prescriber preferences often tilt toward therapies with stronger cardiometabolic outcome positioning and simplified adherence profiles.

Key competitor vectors.

• Class substitution: DPP-4 therapy share is pressured by incretin-based therapies and SGLT2 inhibitors for appropriate patient populations.
• Fixed-dose advantage: Competing single-tablet combinations with once-daily dosing can displace JANUMET where formulary design favors fewer daily administrations.
• Price-led pressure: Generic DPP-4 ingredients compress branded DPP-4 pricing power.

Commercial implication. JANUMET’s net sales trajectory is more sensitive to payer formulary changes than to clinical adoption growth. As the market matures, branded incretin combinations behave like price defenders rather than demand growers.

How does JANUMET compare with sitagliptin/metformin generics on cost and contracting?

The cost comparison between JANUMET and generics is typically decisive in US payer contracting once generics are widely available. Generics remove the branded premium that historically financed rebates and assistance.

How pricing usually plays out.

• When generics are preferred, JANUMET faces tiering pressure that reduces prescription volume even if the brand maintains aggressive net pricing.
• When formularies include JANUMET as an option, payer contracts frequently require higher rebates to match or beat preferred generic economics at the plan level.

What drives net sales more than list price.

• Rebates and discounts that rise as the brand needs to “buy back” share.
• Patient assistance at the pharmacy point of sale.
• Covered lives mix and proportion of Medicare Part D beneficiaries.

What manufacturing and supply-chain factors matter for JANUMET financial performance?

Fixed-dose combinations are sensitive to tablet manufacturing scale and quality. Financial performance can be affected by:

• Batch-level supply constraints that force temporary allocation or substitution.
• Recalls or quality events that can reduce market availability and shift patients to alternative therapies.

In mature markets, however, supply-chain risk is generally a short-term volume disruption rather than a sustained growth driver, unless tied to widespread manufacturing capacity limitations for specific strengths.

How does US diabetes formulary design influence JANUMET revenue?

US revenue trajectory depends on formulary design at the PBM and plan level:

• Preferred tier placement for metformin and generic sitagliptin products.
• Step therapy and prior authorization criteria.
• Use of preferred fixed-dose combination SKUs as “formulary equivalents” to reduce administrative burden.

Featured-snippet style answer. JANUMET revenue is mainly determined by whether plans place branded JANUMET on a preferred tier versus a higher-cost tier or non-preferred status after generic sitagliptin/metformin competition.

What litigation and settlement dynamics shaped JANUMET’s branded commercial life?

For branded combination products exposed to multiple Orange Book-listed patents, the commercialization path typically includes:

• Patent challenges that trigger Paragraph IV litigation and, in some cases, settlements permitting “authorized” generic timing or delayed entry.
• Strength-specific settlements where some dose combinations enter earlier than others.

Market impact pattern.

• Legal timing affects when volume loss accelerates (fixed-dose substitution tends to create discrete share transitions).
• Settlements and design-arounds can shift the competitive landscape from “brand defense” to “generic volume take” in a narrow window.

What is the international market exposure for JANUMET, and what changes the financial outlook?

International performance varies by:

• Regulatory approval status for JANUMET fixed-dose formats.
• Patent coverage and local generic launch schedules.
• Reimbursement systems and price regulation (tender systems, reference pricing, negotiated price cuts).

Commercial implication. Where local generics enter earlier, branded international revenue compresses faster. Where patent barriers or reimbursement caps delay generic fixed-dose uptake, branded revenue lasts longer but still declines as contracting tightens.

What does the competitive landscape suggest for JANUMET’s medium-term financial trajectory?

Given DPP-4 class maturity, widespread generic availability for sitagliptin and metformin, and payer preference for cheaper fixed-dose equivalents and newer incretin-based regimens, JANUMET’s medium-term profile is expected to remain:

• Flat-to-declining in unit demand once generics dominate preferred coverage.
• Increasingly dependent on rebate strategy and patient assistance to hold share.
• More exposed to Medicare Part D and PBM formulary changes than to new clinical adoption.

JANUMET’s “brand value” increasingly reflects patient retention and inertia in fixed-dose regimens rather than expansion of treated populations.

Key takeaways on JANUMET market dynamics and financial trajectory

• JANUMET’s branded sales trajectory is structurally constrained by generic ingredient substitution and DPP-4 class commoditization.
• Net sales growth, when positive, is typically rebate- and contracting-driven, not demand-driven.
• Medium-term revenue exposure is highest from formulary tiering and fixed-dose generic competition at plan level, not from incremental clinical demand.
• The commercial inflection points historically align with Orange Book/patent expiration and any strength-specific generic launches permitted by litigation outcomes.

FAQs

1) Will JANUMET face stronger revenue pressure from fixed-dose generics or from ingredient-level generic substitution?
Fixed-dose generics usually accelerate volume loss more quickly when payers prefer equivalent single-tablet regimens; ingredient-level substitution can still erode share but often at a slower pace due to pill-burden and switching friction.

2) Do Medicare Part D formularies typically reduce JANUMET profitability compared with commercial plans?
Yes. Medicare Part D beneficiary mix and plan design often increase net price pressure through formulary tiering, high rebate expectations, and cost-sharing dynamics.

3) Can newer diabetes therapies reduce JANUMET prescriptions independently of generic availability?
Yes. GLP-1 receptor agonists and SGLT2 inhibitors can shift first- and second-line prescribing, shrinking the addressable population for DPP-4-based regimens even if generics are available.

4) How do JANUMET dose-strength preferences affect competitive substitution?
Plans often prefer specific strengths or dosage forms tied to formulary economics and ease of switching. Strength-level preferences can create “pockets” of retained brand share until those specific SKUs lose coverage.

5) What is the commercial impact if JANUMET availability is disrupted?
Short-term supply issues can cause immediate switching to competitors and may not fully reverse, since prescribers often continue on the alternative product after the patient stabilizes.

---

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-24).
2. FDA. Drug Approval Package for JANUMET (sitagliptin and metformin hydrochloride). (Accessed 2026-07-24).

DrugChatter Q&A for JANUMET

When does the patent for janumet expire?
When did janumet lose exclusivity uk?
When will janumet become generic?
Is there a generic version of janumet?
Janumet tab 50 1000 patent?